{"entity":"astrazeneca","id":"ent_astrazeneca","name":"AstraZeneca","wikidata":"Q731938","page":"https://asof.is/record/astrazeneca","summary":"AstraZeneca is a British-Swedish pharmaceutical company, headquartered in Cambridge. It reported revenue of $58.74B for the period ended December 31, 2025.","title":"AstraZeneca: revenue $58.74B","key_facts":[{"label":"Headquarters","value":"Cambridge","claim":"clm_6B4DC8E0E36A"},{"label":"Revenue","value":"$58.74B","recorded":"58,739,000,000 United States dollar","note":"to 2025-12-31","claim":"clm_75285D1846DF"},{"label":"Ticker","value":"AZN · NYSE","claim":"clm_7F36A4D2B72F"}],"faq":[{"question":"Where is AstraZeneca headquartered?","answer":"Cambridge."},{"question":"What is AstraZeneca's revenue?","answer":"$58.74B for the period ended December 31, 2025."}],"as_of":null,"known_by":null,"since":null,"fact_pages":[{"predicate":"headquarters","page":"https://asof.is/record/astrazeneca/headquarters","md":"https://asof.is/record/astrazeneca/headquarters.md","json":"https://asof.is/v1/entities/astrazeneca/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/astrazeneca/revenue","md":"https://asof.is/record/astrazeneca/revenue.md","json":"https://asof.is/v1/entities/astrazeneca/revenue"},{"predicate":"net_income","page":"https://asof.is/record/astrazeneca/net_income","md":"https://asof.is/record/astrazeneca/net_income.md","json":"https://asof.is/v1/entities/astrazeneca/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/astrazeneca/operating_income","md":"https://asof.is/record/astrazeneca/operating_income.md","json":"https://asof.is/v1/entities/astrazeneca/operating_income"}],"products":[],"coverage":{"entity":"astrazeneca","name":"AstraZeneca","kind":"organization","sources":[{"source":"wikidata","item":"Q731938","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":901832,"ticker":"AZN","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":65,"open":13,"retracted":0,"first":"1995-03-13","predicates":{"total_assets":{"claims":11,"open":1,"kind":"fact"},"revenue":{"claims":11,"open":1,"kind":"fact"},"operating_income":{"claims":11,"open":1,"kind":"fact"},"net_income":{"claims":11,"open":1,"kind":"fact"},"total_equity":{"claims":12,"open":1,"kind":"fact"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":2,"open":1,"kind":"fact"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"cik":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":65,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_327B10FB292B","predicate":"total_equity","value":"48,719,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 48,719,000,000 United States dollar\", as of 2025-12-31. Claim clm_327B10FB292B, https://asof.is/claim/clm_327B10FB292B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm.","url":"https://asof.is/claim/clm_327B10FB292B","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2025, filed 2026-02-24"}},{"id":"clm_75285D1846DF","predicate":"revenue","value":"58,739,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 58,739,000,000 United States dollar\", as of 2025-12-31. Claim clm_75285D1846DF, https://asof.is/claim/clm_75285D1846DF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm.","url":"https://asof.is/claim/clm_75285D1846DF","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2025, filed 2026-02-24"}},{"id":"clm_763AA2791DE9","predicate":"operating_income","value":"13,743,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 13,743,000,000 United States dollar\", as of 2025-12-31. Claim clm_763AA2791DE9, https://asof.is/claim/clm_763AA2791DE9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm.","url":"https://asof.is/claim/clm_763AA2791DE9","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2025, filed 2026-02-24"}},{"id":"clm_7F0BFE9EB1CD","predicate":"net_income","value":"10,233,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 10,233,000,000 United States dollar\", as of 2025-12-31. Claim clm_7F0BFE9EB1CD, https://asof.is/claim/clm_7F0BFE9EB1CD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm.","url":"https://asof.is/claim/clm_7F0BFE9EB1CD","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2025, filed 2026-02-24"}},{"id":"clm_B12E0C1D9275","predicate":"total_assets","value":"114,074,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 114,074,000,000 United States dollar\", as of 2025-12-31. Claim clm_B12E0C1D9275, https://asof.is/claim/clm_B12E0C1D9275, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm.","url":"https://asof.is/claim/clm_B12E0C1D9275","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2025, filed 2026-02-24"}},{"id":"clm_3994638C1B14","predicate":"operating_income","value":"10,003,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 10,003,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_3994638C1B14, https://asof.is/claim/clm_3994638C1B14, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_3994638C1B14","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_763AA2791DE9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2024, filed 2025-02-18"}},{"id":"clm_5BDDB85A5719","predicate":"revenue","value":"54,073,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 54,073,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_5BDDB85A5719, https://asof.is/claim/clm_5BDDB85A5719, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_5BDDB85A5719","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_75285D1846DF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2024, filed 2025-02-18"}},{"id":"clm_702A322E3B09","predicate":"total_equity","value":"40,871,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 40,871,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_702A322E3B09, https://asof.is/claim/clm_702A322E3B09, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_702A322E3B09","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_327B10FB292B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2024, filed 2025-02-18"}},{"id":"clm_DCF412B5DDDA","predicate":"net_income","value":"7,041,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 7,041,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_DCF412B5DDDA, https://asof.is/claim/clm_DCF412B5DDDA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_DCF412B5DDDA","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7F0BFE9EB1CD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2024, filed 2025-02-18"}},{"id":"clm_F05CE2B1D291","predicate":"total_assets","value":"104,035,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 104,035,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_F05CE2B1D291, https://asof.is/claim/clm_F05CE2B1D291, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_F05CE2B1D291","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B12E0C1D9275","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2024, filed 2025-02-18"}},{"id":"clm_1A1A4ACC29CB","predicate":"revenue","value":"45,811,000,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 45,811,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_1A1A4ACC29CB, https://asof.is/claim/clm_1A1A4ACC29CB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465924025553/0001104659-24-025553-index.htm.","url":"https://asof.is/claim/clm_1A1A4ACC29CB","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5BDDB85A5719","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465924025553/0001104659-24-025553-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2023","published_at":"2024-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2023, filed 2024-02-20"}},{"id":"clm_7E98BE75827B","predicate":"operating_income","value":"8,193,000,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 8,193,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_7E98BE75827B, https://asof.is/claim/clm_7E98BE75827B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465924025553/0001104659-24-025553-index.htm.","url":"https://asof.is/claim/clm_7E98BE75827B","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3994638C1B14","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465924025553/0001104659-24-025553-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2023","published_at":"2024-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2023, filed 2024-02-20"}},{"id":"clm_91657DA81B37","predicate":"total_equity","value":"39,166,000,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 39,166,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_91657DA81B37, https://asof.is/claim/clm_91657DA81B37, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465924025553/0001104659-24-025553-index.htm.","url":"https://asof.is/claim/clm_91657DA81B37","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_702A322E3B09","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465924025553/0001104659-24-025553-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2023","published_at":"2024-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2023, filed 2024-02-20"}},{"id":"clm_9F87514064CD","predicate":"net_income","value":"5,961,000,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 5,961,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_9F87514064CD, https://asof.is/claim/clm_9F87514064CD, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465924025553/0001104659-24-025553-index.htm.","url":"https://asof.is/claim/clm_9F87514064CD","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DCF412B5DDDA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465924025553/0001104659-24-025553-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2023","published_at":"2024-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2023, filed 2024-02-20"}},{"id":"clm_CD9BD69D497F","predicate":"total_assets","value":"101,119,000,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 101,119,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_CD9BD69D497F, https://asof.is/claim/clm_CD9BD69D497F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465924025553/0001104659-24-025553-index.htm.","url":"https://asof.is/claim/clm_CD9BD69D497F","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F05CE2B1D291","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465924025553/0001104659-24-025553-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2023","published_at":"2024-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2023, filed 2024-02-20"}},{"id":"clm_31557855C15A","predicate":"revenue","value":"44,351,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 44,351,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_31557855C15A, https://asof.is/claim/clm_31557855C15A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465923023818/0001104659-23-023818-index.htm.","url":"https://asof.is/claim/clm_31557855C15A","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1A1A4ACC29CB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465923023818/0001104659-23-023818-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2022","published_at":"2023-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2022, filed 2023-02-21"}},{"id":"clm_A839065669A3","predicate":"total_assets","value":"96,483,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 96,483,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_A839065669A3, https://asof.is/claim/clm_A839065669A3, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465923023818/0001104659-23-023818-index.htm.","url":"https://asof.is/claim/clm_A839065669A3","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CD9BD69D497F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465923023818/0001104659-23-023818-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2022","published_at":"2023-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2022, filed 2023-02-21"}},{"id":"clm_AE6BE83BCC88","predicate":"net_income","value":"3,293,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 3,293,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_AE6BE83BCC88, https://asof.is/claim/clm_AE6BE83BCC88, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465923023818/0001104659-23-023818-index.htm.","url":"https://asof.is/claim/clm_AE6BE83BCC88","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9F87514064CD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465923023818/0001104659-23-023818-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2022","published_at":"2023-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2022, filed 2023-02-21"}},{"id":"clm_CC377A6E41D1","predicate":"total_equity","value":"37,058,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 37,058,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_CC377A6E41D1, https://asof.is/claim/clm_CC377A6E41D1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465923023818/0001104659-23-023818-index.htm.","url":"https://asof.is/claim/clm_CC377A6E41D1","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_91657DA81B37","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465923023818/0001104659-23-023818-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2022","published_at":"2023-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2022, filed 2023-02-21"}},{"id":"clm_F928384EA602","predicate":"operating_income","value":"3,757,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 3,757,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_F928384EA602, https://asof.is/claim/clm_F928384EA602, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465923023818/0001104659-23-023818-index.htm.","url":"https://asof.is/claim/clm_F928384EA602","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7E98BE75827B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465923023818/0001104659-23-023818-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2022","published_at":"2023-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2022, filed 2023-02-21"}},{"id":"clm_10DEC07C1593","predicate":"operating_income","value":"1,056,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 1,056,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_10DEC07C1593, https://asof.is/claim/clm_10DEC07C1593, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465922025720/0001104659-22-025720-index.htm.","url":"https://asof.is/claim/clm_10DEC07C1593","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F928384EA602","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465922025720/0001104659-22-025720-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2021, filed 2022-02-22"}},{"id":"clm_47272A7D1B25","predicate":"revenue","value":"37,417,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 37,417,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_47272A7D1B25, https://asof.is/claim/clm_47272A7D1B25, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465922025720/0001104659-22-025720-index.htm.","url":"https://asof.is/claim/clm_47272A7D1B25","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_31557855C15A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465922025720/0001104659-22-025720-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2021, filed 2022-02-22"}},{"id":"clm_515C40C5227C","predicate":"total_equity","value":"39,287,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 39,287,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_515C40C5227C, https://asof.is/claim/clm_515C40C5227C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465922025720/0001104659-22-025720-index.htm.","url":"https://asof.is/claim/clm_515C40C5227C","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CC377A6E41D1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465922025720/0001104659-22-025720-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2021, filed 2022-02-22"}},{"id":"clm_BAB2B4420BCE","predicate":"total_assets","value":"105,363,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 105,363,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_BAB2B4420BCE, https://asof.is/claim/clm_BAB2B4420BCE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465922025720/0001104659-22-025720-index.htm.","url":"https://asof.is/claim/clm_BAB2B4420BCE","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A839065669A3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465922025720/0001104659-22-025720-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2021, filed 2022-02-22"}},{"id":"clm_F01EE117485C","predicate":"net_income","value":"115,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 115,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_F01EE117485C, https://asof.is/claim/clm_F01EE117485C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465922025720/0001104659-22-025720-index.htm.","url":"https://asof.is/claim/clm_F01EE117485C","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AE6BE83BCC88","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465922025720/0001104659-22-025720-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2021","published_at":"2022-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2021, filed 2022-02-22"}},{"id":"clm_85B6D134E13C","predicate":"revenue","value":"26,617,000,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 26,617,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_85B6D134E13C, https://asof.is/claim/clm_85B6D134E13C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465921022456/0001104659-21-022456-index.htm.","url":"https://asof.is/claim/clm_85B6D134E13C","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_47272A7D1B25","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465921022456/0001104659-21-022456-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2020","published_at":"2021-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2020, filed 2021-02-16"}},{"id":"clm_B737A429D7E9","predicate":"net_income","value":"3,144,000,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 3,144,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_B737A429D7E9, https://asof.is/claim/clm_B737A429D7E9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465921022456/0001104659-21-022456-index.htm.","url":"https://asof.is/claim/clm_B737A429D7E9","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F01EE117485C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465921022456/0001104659-21-022456-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2020","published_at":"2021-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2020, filed 2021-02-16"}},{"id":"clm_BFC9DC65FD19","predicate":"total_assets","value":"66,729,000,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 66,729,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_BFC9DC65FD19, https://asof.is/claim/clm_BFC9DC65FD19, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465921022456/0001104659-21-022456-index.htm.","url":"https://asof.is/claim/clm_BFC9DC65FD19","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BAB2B4420BCE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465921022456/0001104659-21-022456-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2020","published_at":"2021-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2020, filed 2021-02-16"}},{"id":"clm_D4ADC56D2F76","predicate":"operating_income","value":"5,162,000,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 5,162,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_D4ADC56D2F76, https://asof.is/claim/clm_D4ADC56D2F76, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465921022456/0001104659-21-022456-index.htm.","url":"https://asof.is/claim/clm_D4ADC56D2F76","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_10DEC07C1593","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465921022456/0001104659-21-022456-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2020","published_at":"2021-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2020, filed 2021-02-16"}},{"id":"clm_F30C48EE7B4A","predicate":"total_equity","value":"15,638,000,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 15,638,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_F30C48EE7B4A, https://asof.is/claim/clm_F30C48EE7B4A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465921022456/0001104659-21-022456-index.htm.","url":"https://asof.is/claim/clm_F30C48EE7B4A","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_515C40C5227C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465921022456/0001104659-21-022456-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2020","published_at":"2021-02-16T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2020, filed 2021-02-16"}},{"id":"clm_010DB2BB1408","predicate":"total_assets","value":"61,377,000,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-03-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 61,377,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_010DB2BB1408, https://asof.is/claim/clm_010DB2BB1408, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465920028557/0001104659-20-028557-index.htm.","url":"https://asof.is/claim/clm_010DB2BB1408","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BFC9DC65FD19","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465920028557/0001104659-20-028557-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2019","published_at":"2020-03-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2019, filed 2020-03-03"}},{"id":"clm_08D5EE5A62C8","predicate":"revenue","value":"24,384,000,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-03-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 24,384,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_08D5EE5A62C8, https://asof.is/claim/clm_08D5EE5A62C8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465920028557/0001104659-20-028557-index.htm.","url":"https://asof.is/claim/clm_08D5EE5A62C8","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_85B6D134E13C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465920028557/0001104659-20-028557-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2019","published_at":"2020-03-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2019, filed 2020-03-03"}},{"id":"clm_529E4815C0D2","predicate":"net_income","value":"1,227,000,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-03-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 1,227,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_529E4815C0D2, https://asof.is/claim/clm_529E4815C0D2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465920028557/0001104659-20-028557-index.htm.","url":"https://asof.is/claim/clm_529E4815C0D2","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B737A429D7E9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465920028557/0001104659-20-028557-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2019","published_at":"2020-03-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2019, filed 2020-03-03"}},{"id":"clm_7E8748E6B574","predicate":"total_equity","value":"14,596,000,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-03-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 14,596,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_7E8748E6B574, https://asof.is/claim/clm_7E8748E6B574, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465920028557/0001104659-20-028557-index.htm.","url":"https://asof.is/claim/clm_7E8748E6B574","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F30C48EE7B4A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465920028557/0001104659-20-028557-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2019","published_at":"2020-03-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2019, filed 2020-03-03"}},{"id":"clm_CA91157E8FEC","predicate":"operating_income","value":"2,924,000,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-03-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 2,924,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_CA91157E8FEC, https://asof.is/claim/clm_CA91157E8FEC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465920028557/0001104659-20-028557-index.htm.","url":"https://asof.is/claim/clm_CA91157E8FEC","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D4ADC56D2F76","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465920028557/0001104659-20-028557-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2019","published_at":"2020-03-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2019, filed 2020-03-03"}},{"id":"clm_0928C69F436C","predicate":"operating_income","value":"3,387,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-03-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 3,387,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_0928C69F436C, https://asof.is/claim/clm_0928C69F436C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465919012881/0001104659-19-012881-index.htm.","url":"https://asof.is/claim/clm_0928C69F436C","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CA91157E8FEC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465919012881/0001104659-19-012881-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2018","published_at":"2019-03-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2018, filed 2019-03-05"}},{"id":"clm_39BC161464CE","predicate":"total_assets","value":"60,651,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-03-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 60,651,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_39BC161464CE, https://asof.is/claim/clm_39BC161464CE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465919012881/0001104659-19-012881-index.htm.","url":"https://asof.is/claim/clm_39BC161464CE","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_010DB2BB1408","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465919012881/0001104659-19-012881-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2018","published_at":"2019-03-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2018, filed 2019-03-05"}},{"id":"clm_4F65B3C1FC28","predicate":"total_equity","value":"14,044,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-03-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 14,044,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_4F65B3C1FC28, https://asof.is/claim/clm_4F65B3C1FC28, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465919012881/0001104659-19-012881-index.htm.","url":"https://asof.is/claim/clm_4F65B3C1FC28","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7E8748E6B574","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465919012881/0001104659-19-012881-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2018","published_at":"2019-03-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2018, filed 2019-03-05"}},{"id":"clm_790001197E10","predicate":"revenue","value":"22,090,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-03-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 22,090,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_790001197E10, https://asof.is/claim/clm_790001197E10, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465919012881/0001104659-19-012881-index.htm.","url":"https://asof.is/claim/clm_790001197E10","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_08D5EE5A62C8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465919012881/0001104659-19-012881-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2018","published_at":"2019-03-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2018, filed 2019-03-05"}},{"id":"clm_80CF1A157103","predicate":"net_income","value":"2,050,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-03-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 2,050,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_80CF1A157103, https://asof.is/claim/clm_80CF1A157103, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465919012881/0001104659-19-012881-index.htm.","url":"https://asof.is/claim/clm_80CF1A157103","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_529E4815C0D2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465919012881/0001104659-19-012881-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2018","published_at":"2019-03-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2018, filed 2019-03-05"}},{"id":"clm_10CF439A8D3D","predicate":"total_assets","value":"63,354,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 63,354,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_10CF439A8D3D, https://asof.is/claim/clm_10CF439A8D3D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_10CF439A8D3D","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_39BC161464CE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_6A3694B18261","predicate":"total_equity","value":"16,642,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 16,642,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_6A3694B18261, https://asof.is/claim/clm_6A3694B18261, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_6A3694B18261","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4F65B3C1FC28","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_77DE63410430","predicate":"operating_income","value":"3,677,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 3,677,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_77DE63410430, https://asof.is/claim/clm_77DE63410430, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_77DE63410430","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0928C69F436C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_7BDCCD2AEF61","predicate":"net_income","value":"2,868,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 2,868,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_7BDCCD2AEF61, https://asof.is/claim/clm_7BDCCD2AEF61, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_7BDCCD2AEF61","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_80CF1A157103","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_B25F0718A827","predicate":"revenue","value":"22,465,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 22,465,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_B25F0718A827, https://asof.is/claim/clm_B25F0718A827, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_B25F0718A827","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_790001197E10","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_194B34501880","predicate":"net_income","value":"3,406,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 3,406,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_194B34501880, https://asof.is/claim/clm_194B34501880, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_194B34501880","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7BDCCD2AEF61","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_4B2074B77E0B","predicate":"total_assets","value":"62,526,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 62,526,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_4B2074B77E0B, https://asof.is/claim/clm_4B2074B77E0B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_4B2074B77E0B","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_10CF439A8D3D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_654CC8AE2812","predicate":"operating_income","value":"4,902,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 4,902,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_654CC8AE2812, https://asof.is/claim/clm_654CC8AE2812, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_654CC8AE2812","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_77DE63410430","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_904F793B66AA","predicate":"revenue","value":"23,002,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 23,002,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_904F793B66AA, https://asof.is/claim/clm_904F793B66AA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_904F793B66AA","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B25F0718A827","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_B272D51F85BC","predicate":"total_equity","value":"16,669,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 16,669,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_B272D51F85BC, https://asof.is/claim/clm_B272D51F85BC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_B272D51F85BC","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6A3694B18261","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_39CC74EC0018","predicate":"total_assets","value":"60,056,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 60,056,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_39CC74EC0018, https://asof.is/claim/clm_39CC74EC0018, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_39CC74EC0018","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4B2074B77E0B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_4F3F4354CA13","predicate":"total_equity","value":"18,509,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 18,509,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_4F3F4354CA13, https://asof.is/claim/clm_4F3F4354CA13, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_4F3F4354CA13","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B272D51F85BC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_9CE71799FE73","predicate":"operating_income","value":"4,114,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 4,114,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_9CE71799FE73, https://asof.is/claim/clm_9CE71799FE73, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_9CE71799FE73","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_654CC8AE2812","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_DEF1603E885B","predicate":"net_income","value":"2,826,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 2,826,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_DEF1603E885B, https://asof.is/claim/clm_DEF1603E885B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_DEF1603E885B","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_194B34501880","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_E7354F8FC4AB","predicate":"revenue","value":"24,708,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 24,708,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_E7354F8FC4AB, https://asof.is/claim/clm_E7354F8FC4AB, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_E7354F8FC4AB","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_904F793B66AA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_1A634ECF5C3D","predicate":"total_equity","value":"19,646,000,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-12-31","published":"2018-03-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 19,646,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_1A634ECF5C3D, https://asof.is/claim/clm_1A634ECF5C3D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm.","url":"https://asof.is/claim/clm_1A634ECF5C3D","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4F3F4354CA13","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465918015257/0001104659-18-015257-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2017","published_at":"2018-03-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2017, filed 2018-03-06"}},{"id":"clm_CC0A4381A0A0","predicate":"registrant_name","value":"ASTRAZENECA PLC","valid_from":"1999-02-05","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca registrant name: ASTRAZENECA PLC\", as of 1999-02-05. Claim clm_CC0A4381A0A0, https://asof.is/claim/clm_CC0A4381A0A0, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_CC0A4381A0A0","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_5C035E7A6F9A","predicate":"registrant_name","value":"ZENECA GROUP PLC","valid_from":"1995-03-13","valid_to":"1999-02-05","published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca registrant name: ZENECA GROUP PLC\", as of 1995-03-13 (until 1999-02-05). Claim clm_5C035E7A6F9A, https://asof.is/claim/clm_5C035E7A6F9A, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_5C035E7A6F9A","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CC0A4381A0A0","sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_26C4F27CEF84","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_26C4F27CEF84, https://asof.is/claim/clm_26C4F27CEF84, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_26C4F27CEF84","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_43376D897A1F","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca listed on: NYSE\", undated. Claim clm_43376D897A1F, https://asof.is/claim/clm_43376D897A1F, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_43376D897A1F","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_433F982364C7","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca fiscal year end: 12-31\", undated. Claim clm_433F982364C7, https://asof.is/claim/clm_433F982364C7, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_433F982364C7","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_6B4DC8E0E36A","predicate":"headquarters","value":"Cambridge","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca headquarters: Cambridge\", undated. Claim clm_6B4DC8E0E36A, https://asof.is/claim/clm_6B4DC8E0E36A, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_6B4DC8E0E36A","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_7F36A4D2B72F","predicate":"ticker","value":"AZN","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca ticker: AZN\", undated. Claim clm_7F36A4D2B72F, https://asof.is/claim/clm_7F36A4D2B72F, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_7F36A4D2B72F","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_8352C183E226","predicate":"state_of_incorporation","value":"X0","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca state of incorporation: X0\", undated. Claim clm_8352C183E226, https://asof.is/claim/clm_8352C183E226, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_8352C183E226","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_8820826D4245","predicate":"cik","value":"0000901832","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca cik: 0000901832\", undated. Claim clm_8820826D4245, https://asof.is/claim/clm_8820826D4245, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_8820826D4245","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}